Comparative efficacy and safety of the trastuzumab biosimilar HLX02 versus originator trastuzumab in the neoadjuvant THP-EC regimen for early-stage HER2-positive breast cancer: a real-world study

View at Publisher

Ask AI

Bookmark

Share

Key Points

This study aims to compare the efficacy and safety of the trastuzumab biosimilar HLX02 and the originator trastuzumab in early-stage HER2-positive breast cancer.
Conducted a real-world comparison of HLX02 and trastuzumab
Evaluated efficacy and safety in early-stage HER2-positive breast cancer using the THP-EC regimen
Assessments included clinical outcomes and treatment-related adverse effects.
HLX02 demonstrated equal efficacy to originator trastuzumab
Safety profiles of HLX02 and trastuzumab were comparable
HLX02 is suggested as a cost-effective alternative.

A real-world study demonstrates equivalent efficacy and safety of HLX02 in HER2-positive breast cancer, suggesting a cost-effective approach.

HLX02 demonstrated equivalent efficacy and safety to the originator trastuzumab in this setting, representing a cost-effective treatment alternative.

No takes yet. Share an insight, caveat, or question.

Wang et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share